Obsessive-Compulsive Disorder News

The FDA has approved an investigational new drug application from Ceruvia Lifesciences to conduct a phase 2 clinical trial to determine the safety and efficacy of synthetic psilocybin for the treatment of obsessive-compulsive disorder.

Exposure and response prevention treatment through video teletherapy showed effectiveness in reducing obsessive-compulsive symptoms while improving quality of life, per a study published in the Journal of Medical Internet Research.

NEW ORLEANS – Family member involvement or previous diagnoses of depression or obsessive-compulsive disorder is most likely how extremists and conspiracy theorists end up in psychiatric care, Jack S. Rozel, MD, said.

NEW ORLEANS – The American Psychiatric Association DSM steering committee gathered at the APA annual meeting to review proposed changes to the manual, committee chair Paul S. Appelbaum, MD, said.

NEW ORLEANS – For the first time in 3 years, the American Psychiatric Association will host its annual meeting in person, May 21 to 25 in New Orleans, with social determinants of mental health as the conference theme.

The FDA has approved Neuronetics’ transcranial magnetic stimulation system, called NeuroStar, as an adjunct treatment for adults with obsessive compulsive disorder.

The American Psychiatric Association on Wednesday announced the launch of PsychPRO 2.0, a mental health registry that offers psychiatrists enhanced options to engage with patients, track outcomes and streamline data for quality reporting.

DENVER — Multiple socioeconomic and clinician-based factors prevent access to and utilization of exposure and response prevention therapy for youths, a speaker said at the Anxiety and Depression Association of America annual conference.

DENVER — Exposure and response therapy improves with increased engagement, participation and humor, according to a panel of experts at the Anxiety and Depression Association of America annual conference.

DENVER – Successful cognitive behavioral therapy for body dysmorphic disorder must be mindful of patient engagement and assessment, according to a presentation at the Anxiety and Depression Association of America annual conference.